Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

Jubilant Pharmova Limited's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 1.65300
forwardPE 23.38843
debtToEquity 43.77600
earningsGrowth 0.00000
revenueGrowth 0.09700
grossMargins 0.67973
operatingMargins 0.12972
trailingEps 52.80000
forwardEps 0.00000

Jubilant Pharmova Limited's current ratio of 1.653 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects Jubilant Pharmova Limited's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
JUBLPHARMA's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

The current price of JUBLPHARMA, when assessed against projections, reveals no significant risks or opportunities. This situation indicates a steady market environment, prompting investors to remain patient until more clarity emerges regarding the stock's potential.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


JUBLPHARMA saw 1 buying transactions, each while market price hovered at 1219.5999755859375.There were no buy transactions during the given period.The higher volume of sells at JUBLPHARMA's current price levels could indicate potential for further price drops. If this selling trend continues, investors might expect the stock's value to decline as more shareholders exit their positions.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


JUBLPHARMA has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view JUBLPHARMA as a stable option to park their money and potentially benefit from the company's continued growth and profitability.